Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

Harold J. Burstein, MD, PhD
Published: Wednesday, Jul 12, 2017



Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

The APT trial was an adjuvant study investigating 400 women with stage I HER2-positive breast cancer. The patients received treatment with trastuzumab and paclitaxel. There was a 97% 5-year disease-free survival showing encouraging results, states Burstein.

SELECTED
LANGUAGE


Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

The APT trial was an adjuvant study investigating 400 women with stage I HER2-positive breast cancer. The patients received treatment with trastuzumab and paclitaxel. There was a 97% 5-year disease-free survival showing encouraging results, states Burstein.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x